Effect of tumor necrosis factor-alpha on triglyceride and phospholipid content and fatty acid composition of liver and carcass in rats.
We have previously shown that a continuous infusion of tumor necrosis factor-alpha (TNF-alpha) in rats results in an increase in plasma triglyceride (TG), liver protein and DNA, and at the same time a reduction in muscle protein. However, there is no information on the associated effects of TNF-alpha on liver and muscle lipids. The present study, therefore, determined the effect of TNF-alpha on the TG and phospholipid (PL) content and their fatty acid composition, in the liver and carcass of rats and correlated with the plasma levels of insulin, corticosterone, and catecholamines. Total parenteral nutrition that met the daily nutrient requirements was continuously infused for 10 d through a central vein catheter in two groups of rats, one receiving infused TNF-alpha (100 micrograms/kg/d) and a control group. Hepatic TG and PL, expressed either as mg/g dry weight or total organ content, were significantly increased in the TNF-alpha-infused group compared with controls. Livers of TNF-alpha infused rats contained significantly less saturated and monounsaturated fatty acids and significantly more polyunsaturated fatty acids (PUFA) of the omega 3 and omega 6 series than controls. The carcass, on the other hand, contained significantly more monounsaturated and significantly less polyunsaturated fatty acids of the omega 6 series than controls. There were no changes in corticosterone level. Although plasma glucose levels were comparable between control and TNF-alpha infused rats, the latter had a marked increase in insulin levels, demonstrating insulin resistance. In addition TNF-alpha infused rats had raised norepinephrine levels.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D003345:Corticosterone / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism*; D005229:Fatty Acids, Monounsaturated / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D007328:Insulin / Q000097:blood; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010743:Phospholipids / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D005231:Fatty Acids, Unsaturated; D007328:Insulin; D008041:Linoleic Acids; D010743:Phospholipids; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D016718:Arachidonic Acid; D019787:Linoleic Acid; D003345:Corticosterone; D009638:Norepinephrine